Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Second-line afatinib significantly improves PFS in metastatic head and neck cancer

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction

Current treatment options in mRCC

Additional treatment options impact first-line treatment of mRCC: No

Additional treatment options impact first-line treatment of mRCC: Yes

Discussion: Additional treatment options impact first-line treatment of mRCC

From clinical trial to clinical practice: Evidence from the real world

What have we learned? Expert perspectives

IEO to have a new Scientific Director at the end of the year when Prof Umberto Veronesi hands over the role to Prof Roberto Orecchia